We report our experience with high-dose chemotherapy (HDC) and autologous SCT (ASCT) in 66 patients out of 113 (113 patients out of 153 had complete analysis) with primary refractory Hodgkin's lymphoma (PR-HL) who received salvage chemotherapy followed by BEAM as HDC. Median age at ASCT was 23 years. Before salvage chemotherapy, stages I:II:III:IV were 2:21:14:29, bulky disease 27%, involvement of mediastinum 79%, spleen 26% and extranodal site 47%; 92% had ESHAP (etoposide, methylprednisolone, high-dose cytarabine, cisplatin) as salvage. Post-ASCT evaluation showed response in 50 patients (76%), complete response (CR) in 37 (56%), partial response in 14 (21%), no response or stable disease in three (5%) and progressive disease in 10 (15%) patients. Six patients achieved CR after XRT (5) or surgery (1), making a total with CR of 43 (65%). From diagnosis and HDC, median follow-up is 38.5 and 22.8 months and median overall survival 78 and 57 months, respectively. EFS and overall survival (OS) are 36 and 64%, respectively. In all 47% patients are in CR. Twentytwo (33%) patients died of the disease. Multivariate analysis showed elevated lactic dehydrogenase (LDH) for EFS (P ¼ 0.041) and mediastinal involvement for OS (P ¼ 0.038) as negative prognostic factors. In conclusion, EFS and OS are only 36 and 64%, respectively. Elevated LDH and mediastinal involvement are poor prognostic factors.
Introduction
Multiagent chemotherapy alone or in combination with radiation therapy (XRT) cures more than 80% of patients with Hodgkin's lymphoma (HL). 1 High-dose chemotherapy and autologous SCT (HDC ASCT) for patients with HL who have persistent disease or relapse after chemotherapy/combination treatment has shown superior EFS when compared with salvage chemotherapy alone. 2, 3 Patients with primary refractory Hodgkin's lymphoma (PR-HL) who received salvage chemotherapy had extremely poor outcome. 4, 5 Being the main transplant center for the entire Kingdom of Saudi Arabia, more than 200 stem cell transplants are performed every year at King Faisal Specialist Hospital and Research Center.
We retrospectively analyzed our patients who underwent HDC ASCT for PR-HL.
Patients and methods
This is a retrospective cohort analysis. From 1996 to October 2007, total of 231 patients underwent HDC ASCT for non-Hodgkin's lymphoma (NHL) (78 patients) and HL (153 patients) in the Section of Adult Medical Oncology. Of these 153 HL patients, 113 had completed analysis for prognostic factors and 66 of these 113 had PR-HL. PR-HL is defined as PR, NR/SD or PD after planned multiagent chemotherapy with or without XRT, or relapsing within 3 months of finishing the planned treatment after achieving complete response (CR) or CR unconfirmed (CRu). Except for a few patients, infusional ESHAP (etoposide, solumedrol, Ara-C, cisplatin), was primarily used as salvage chemotherapy and response evaluation after two to three cycles of salvage chemotherapy. Responding or stable HL patients received the same chemotherapy as mobilization regimen for stem cell collection followed by HDC ASCT. BEAM (BCNU, etoposide, Ara-C, melphalan) was used as HDC. Patients had appropriate restaging radiological evaluation after HDC ASCT, preferably around day 100 to check the disease status. Patients with clinical suspension of relapse or progression after HDC ASCT had appropriate restaging work-up as required.
Prognostic factors evaluation
Data were collected both at the time of diagnosis and prior to the initiation of salvage chemotherapy (after induction failure). This is shown in Table 1 .
Statistical analysis SPSS Version 14 was used for statistical analyses. Survival analyses were performed using the Kaplan and Meier method and compared using the log-rank test. Event is defined as the presence of disease after HDC ASCT, death due to any cause or relapse after HDC ASCT. EFS is calculated from the date of stem cell infusion. Impact of prognostic factors (at the time of relapse or progression prior to the start of salvage chemotherapy) were evaluated using one-way analysis of variance (ANOVA) and multivariate regression analysis for OS and EFS as dependent variables.
Results
Sixty-six patients with PR-HL were identified. Of these, 38 (58%) had biopsy-proven reconfirmation of disease at the time of relapse/progression. Other patients had unequivocal evidence of PR-HL based on clinical and radiological evaluation.
ESHAP was the primary salvage chemotherapy. Patient characteristics and different prognostic factors are shown in Table 1 . Fifty-seven (86%) patients had ESHAP þ G-CSF as mobilization regimen. Source of stem cell was peripheral blood stem cells in 63 patients, bone marrow harvest þ peripheral blood in two and bone marrow harvest in one patient.
Response evaluation after salvage chemotherapy/before HDC ASCT showed that 13 (20%) patients were in CR/CRu, 42 (64%) had PR and 11 (17%) had NR or SD.
Post-HDC ASCT evaluation
Neutrophil engraftment was 100%, but two patients failed platelet engraftment by day 28.
Four patients with PR after HDC ASCT and one with PD achieved CR after XRT. One patient who had persistent localized inguinal area disease, even after radiation therapy post-HDC ASCT, had surgical resection and is disease-free (14 months follow-up after surgery). One patient who had localized relapse after HDC ASCT also achieved CR after XRT. All these patients are in continuous CR (CCR). In all 24 of 53 patients (45%) with PR/NR/SD after salvage chemotherapy achieved CR after HDC ASCT (13, i.e. 20%, patients were in CR after ESHAP). Combining all the CR/CRu/CCR and also the CR that resulted from XRT post-HDC ASCT or surgical resection in one case, a total of 43 (65%) patients achieved CR.
Follow-up and survival analysis
Eight alive patients (12%) had o12 months follow-up; median follow-up from diagnosis is 38.5 months and from HDC and ASCT, 22.8 months. Median overall survival from diagnosis is 78 months and from HDC ASCT, 57 months. At the time of current evaluation as of 1 March 2007, 13 (20% of 66 patients and 30% of 43 who achieved CR) had relapsed. Thirty-one (47%) patients are still in CCR. Twenty-two (33%) patients died of disease and 11 (17%) are alive with disease. Forty-two (64%) patients had an event and EFS is only 36%. OS is 64%, although the follow-up is relatively short. Median OS has not yet been reached. Two patients had treatment-related mortality, one due to diffuse pulmonary hemorrhage on day þ 6, and the other patient developed post-HDC and ASCT biopsyproven diffuse interstitial pneumonitis with diffuse alveolar damage and died 3 months after transplant.
Impact of prognostic factors on EFS and OS EFS with elevated lactic dehydrogenase (LDH) vs normal LDH (Fisher's exact test) was 19 vs 42% (P ¼ 0.09), respectively, and on multivariate analysis, P ¼ 0.041. Mortality with mediastinal involvement vs no involvement (Fisher's exact test) was 44 vs 12.5% (P ¼ 0.02), respectively, and on multivariate analysis, P ¼ 0.038. Response to salvage chemotherapy was first grouped as CR/CRu/PR vs NR/SD for multivariate analysis among all other factors in Table 2 . This failed to show any effect on EFS and OS. When response was grouped as CR/CRu vs PR/NR/SD for multivariate analysis among all other factors, P-value was 0.047 for EFS and 0.34 for OS. It is important to recall that all patients with progressive disease on salvage were excluded from HDC ASCT. The outcome of HDC ASCT in PR-HL is not as encouraging as in relapsed HL. Most studies have reported the results of relapsed and refractory HL combined together. This has resulted in less than optimal outcome for relapsed and more than expected for PR-HL patients. Studies reporting these two clinical situations separately are limited. There is no common definition for PR-HL. Some studies selected patients the way we did, [6] [7] [8] [9] [10] but some used even more strict criteria, [11] [12] [13] [14] [15] that is, patients with disease progression while on chemotherapy or progression within 3 months after PR. Comparison of patients with PR-HL who had HDC ASCT with other treatment modality such as salvage chemotherapy or radical XRT is limited to few randomized trials 2, 3 and mainly non-randomized reports or subset analysis. 7, 8, 12, 16, 17 These reports have varying results anywhere from as good as HDC ASCT (for EFS) to worse than HDC ASCT. It is also difficult to compare salvage chemotherapy alone vs HDC ASCT, as most patients who have chemosensitive disease to salvage chemotherapy usually proceed to HDC ASCT and those who are progressing are not usually offered HDC ASCT, 8 ASCT program. Morabito et al. 17 also reported that 29% of patients were not candidates for curative intent therapy. In their analysis, HDC ASCT clearly showed survival benefit over conventional dose salvage chemotherapy, 4-year OS 81 vs 38%. Some other studies had also reported superior EFS favoring HDC ASCT over salvage chemotherapy alone. 7, 12, 16 Many other studies had reviewed the outcome and impact of various prognostic factors, 18-23 which we had reported in tabular form. 24 Our data derive from a large single institution to report the outcome of PR-HL. It is different from many published studies as we have younger patients, minimal pretreatment, early HDC ASCT offered, reporting only HL, exclusively used ESHAP as salvage, high percentage of tissue reconfirmation at progression, and had uniform guidelines for all patients. Our results are the same as any other report; the main limitation is the relatively short follow-up.
We thoroughly reviewed the impact of prognostic factors in this group of patients and identified elevated LDH and mediastinal involvement as negative prognostic factors. EFS with elevated LDH vs normal LDH (Fisher's exact test) was 19 vs 42% (P ¼ 0.09), respectively, and on multivariate analysis, P ¼ 0.041. Mortality with mediastinal involvement vs no involvement (Fisher's exact test) was 44 vs 12.5% (P ¼ 0.02) respectively, and on multivariate analysis, P ¼ 0.038. Only CR/CRu vs PR/NR/SD had a P-value of 0.047 for EFS. This effect was lost when CR/ CRu/PR vs NR/SD was used. EFS of only 36% at a median follow-up of 22.8 months signifies uniformly poor prognosis for patients with PR-HL despite HDC ASCT. Most studies have reported prognostic factors for the whole group, and a separate analysis of these factors in the PR-HL setting is limited.
In patients with PR-HL, ESHAP þ BEAM combination ±XRT resulted in a 76% response rate and a 65% CR rate. Despite this high responsiveness, 30% of patients with CR relapsed. In all 33% patients had died after HDC ASCT. For EFS, elevated LDH and OS, mediastinal involvement is a negative prognostic factor. At a median follow-up of 22.8 months from HDC ASCT, EFS is only 36%. Our results are comparable with other reports. The main limitation is relatively a short follow-up. Despite these results, HDC ASCT is considered the standard option for this group. Better treatment strategies are urgently required for this group of patient population. 
